XML 91 R68.htm IDEA: XBRL DOCUMENT v3.25.2
Subsequent Events (Additional Information (Details)
Apr. 17, 2025
shares
Feb. 28, 2025
Days
Feb. 22, 2025
USD ($)
Jan. 02, 2025
USD ($)
shares
Feb. 29, 2024
$ / shares
shares
Mar. 31, 2025
shares
Jan. 21, 2025
shares
Dec. 31, 2024
shares
Jun. 18, 2024
shares
Jun. 11, 2024
shares
Dec. 31, 2023
shares
Oct. 11, 2023
$ / shares
Sep. 25, 2023
shares
Sep. 21, 2023
shares
Subsequent Event [Line Items]                            
Amortization payment | $       $ 1,100,000                    
Class of Warrant or Right, Outstanding               5,467,692     6,854,309      
Common Warrants Purchase               7,142            
Combined Price Paid Of Warrant | $ / shares         $ 54.74                  
Common stock, shares issued           6,951,622   6,951,622 3,250,000 3,250,000     13,562 8,500,000
Maximum [Member]                            
Subsequent Event [Line Items]                            
Debt conversion price | $ / shares                       $ 70    
Minimum [Member]                            
Subsequent Event [Line Items]                            
Debt conversion price | $ / shares                       $ 17.5    
Scilex Pharma [Member]                            
Subsequent Event [Line Items]                            
Total Number of Shares Granted       142,855                    
Rodman & Renshaw LLC                            
Subsequent Event [Line Items]                            
Common stock sold         168,068                  
Common Warrants Purchase         168,068                  
Public Offering Price | $ / shares         $ 59.5                  
ZTlido Rest of World License Agreement [Member]                            
Subsequent Event [Line Items]                            
Percentage of Lidocaine Topical System     1.80%                      
Aggregate Payment Of Company | $     $ 200,000                      
ZTlido Rest of World License Agreement [Member] | Scilex Pharma [Member]                            
Subsequent Event [Line Items]                            
Percentage of net revenue     50.00%                      
ZTlido Rest of World License Agreement [Member] | Forecast [Member]                            
Subsequent Event [Line Items]                            
Percentage of Lidocaine Topical System     1.80%                      
Aggregate Payment Of Company | $     $ 200,000                      
ZTlido Rest of World License Agreement [Member] | Forecast [Member] | Scilex Pharma [Member]                            
Subsequent Event [Line Items]                            
Percentage of net revenue     50.00%                      
Gloperba-Elyxyb Royalty Purchase Agreement [Member]                            
Subsequent Event [Line Items]                            
Percentage of aggregate net sales   4.00%                        
No of calendar days | Days   60                        
Gloperba-Elyxyb Royalty Purchase Agreement [Member] | Forecast [Member]                            
Subsequent Event [Line Items]                            
Percentage of aggregate net sales   4.00%                        
No of calendar days | Days   60                        
Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member]                            
Subsequent Event [Line Items]                            
Initial principal amount | $       $ 6,250,000                    
Redemption Premium       100.00%                    
Common Stock [Member]                            
Subsequent Event [Line Items]                            
Shares delivered           92,857                
Subsequent Event [Member]                            
Subsequent Event [Line Items]                            
Amortization payment | $       $ 1,100,000                    
Ownership Interest Rate 60.00%                          
Subsequent Event [Member] | Three i LP [Member]                            
Subsequent Event [Line Items]                            
Total Number of Shares Granted       14,285                    
Subsequent Event [Member] | Scilex Pharma [Member]                            
Subsequent Event [Line Items]                            
Total Number of Shares Granted       142,855                    
Subsequent Event [Member] | Oramed [Member]                            
Subsequent Event [Line Items]                            
Total Number of Shares Granted       71,428                    
Subsequent Event [Member] | BPY Limited [Member]                            
Subsequent Event [Line Items]                            
Total Number of Shares Granted       20,571                    
Subsequent Event [Member] | Nomis Bay Ltd [Member]                            
Subsequent Event [Line Items]                            
Total Number of Shares Granted       36,571                    
Subsequent Event [Member] | Scilex Bio JV                            
Subsequent Event [Line Items]                            
Ownership Interest Rate 40.00%                          
Common stock, shares issued 5,000,000                          
Subsequent Event [Member] | Deferral and Consent Under Tranche B Senior Secured Convertible Note [Member]                            
Subsequent Event [Line Items]                            
Initial principal amount | $       $ 6,250,000                    
Redemption Premium       100.00%                    
Subsequent Event [Member] | Common Stock [Member]                            
Subsequent Event [Line Items]                            
Shares delivered             92,857